Sandoz Group Ltd Sponsored ADR (SDZNY) Price & Analysis

Compare

90 Followers

SDZNY Stock Chart & Stats

$75.80

$0.55(1.34%)

At close: Jan 08 4:00 PM EST

$75.80

$0.55(1.34%)

Day’s Range― - ―

52-Week Range$36.26 - $86.79

Previous CloseN/A

Volume11.52K

Average Volume (3M)12.74K

Market Cap

$37.81B

Enterprise Value$41.58B

Total Cash (Recent Filing)$1.39B

Total Debt (Recent Filing)$5.69B

Price to Earnings (P/E)162.4

Beta0.40

Next Earnings

Feb 25, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.98%

Share Statistics

EPS (TTM)0.88

Shares Outstanding440,000,000

10 Day Avg. Volume34,453

30 Day Avg. Volume12,739

Financial Highlights & Ratios

PEG Ratio-174.11

Price to Book (P/B)2.13

Price to Sales (P/S)1.68

P/FCF Ratio290.18

Enterprise Value/Market Cap1.10

Enterprise Value/Revenue4.62

Enterprise Value/Gross Profit9.85

Enterprise Value/Ebitda49.88

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Biosimilars Scale & PipelineBiosimilars now comprise a material share of sales and a deep pipeline targets large originator markets. This shifts revenue mix toward higher-value biologics, leverages regulatory barriers to entry, and supports durable growth and margin improvement as uptake continues over multiple years.

Manufacturing Capacity & M&AExpanding manufacturing footprint and acquiring specialized biologics facilities increase vertical integration and capacity for complex products. Greater in-house capabilities reduce supply risk, shorten time-to-market for biosimilars, and create scalable cost advantages that persist beyond short-term cycles.

Improved Cash GenerationSubstantially higher free cash flow provides durable financial flexibility to fund R&D, capex, and strategic M&A without relying solely on external financing. Strong cash conversion underpins balance sheet resilience and the ability to absorb one-off separation costs while investing in growth initiatives.

Bears Say

Weak Reported ProfitabilityZero net income and a compressed EBIT margin indicate persistent profitability pressure despite solid gross margins. Continued weak operating income can limit reinvestment, slow deleveraging, and constrain returns to shareholders unless operational efficiency and pricing mix sustainably improve.

Generics Price ErosionRecurring price deflation in small‑molecule generics is a structural headwind that compresses margins over time. Without scale gains, portfolio rebalancing, or higher-margin product growth, persistent price erosion will pressure long-term profitability and require continual productivity or portfolio shifts.

Separation & Restructuring CostsLarge separation and rationalization charges are draining near-term earnings and cash. Even if one-time, these costs reduce funding available for growth and increase execution risk around manufacturing rationalization and integration of acquisitions, potentially delaying expected benefits.

Sandoz Group Ltd Sponsored ADR News

Sandoz receives U.S. FDA approval to expand Enzeevu label

Sandoz (SDZNY) announced that the US Food and Drug Administration, FDA, has approved an expanded label for Enzeevu,...

3d ago

Sandoz upgraded to Buy from Hold at Jefferies

Jefferies analyst James Vane-Tempest upgraded Sandoz (SDZNY) to Buy from Hold with a price target of CHF 75,...

10d ago

Sandoz price target raised to CHF 63 from CHF 60 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Sandoz (SDZNY) to CHF 63 from CHF 60 and keeps...

29d ago

Sandoz price target raised to CHF 55 from CHF 49 at Berenberg

Berenberg raised the firm’s price target on Sandoz (SDZNY) to CHF 55 from CHF 49 and keeps a...

29d ago

Sandoz price target raised to CHF 63 from CHF 60 at Deutsche Bank

Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Sandoz (SDZNY) to CHF 63 from CHF...

1M ago

Sandoz price target raised to CHF 70 from CHF 55 at Barclays

Barclays raised the firm’s price target on Sandoz (SDZNY) to CHF 70 from CHF 55 and keeps an...

2M ago

Sandoz initiated with a Neutral at Oddo BHF

Oddo BHF analyst Martial Descoutures initiated coverage of Sandoz (SDZNY) with a Neutral rating and CHF 57 price...

2M ago

Sandoz price target raised to CHF 60 from CHF 55 at Deutsche Bank

Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Sandoz (SDZNY) to CHF 60 from CHF...

3M ago

Sandoz price target raised to CHF 60 from CHF 55 at JPMorgan

JPMorgan raised the firm’s price target on Sandoz (SDZNY) to CHF 60 from CHF 55 and keeps an...

3M ago

Evotec to sell Just – Evotec Biologics EU, license technology to Sandoz

Evotec (EVO) announced the successful signing of the sale of the Just – Evotec Biologics Toulouse site to...

4M ago

EVO

Sandoz Group Reports Strong H1 2025 Financial Results

Sandoz Group Ltd Sponsored ADR ( ($SDZNY) ) has released its Q2 earnings. Here is a breakdown of...

7M ago

SDZNY

Sandoz Group Ltd’s Strategic Growth Amid Market Challenges

Sandoz Group Ltd Sponsored ADR (($SDZNY)) has held its Q2 earnings call. Read on for the main highlights...

7M ago

SDZNY

Sandoz Group Reports Strong Growth and Strategic Advancements

Sandoz Group Ltd Sponsored ADR ( ($SDZNY) ) has released its Q4 earnings. Here is a breakdown of...

12M ago

SDZNY

Sandoz Group Ltd: Strong Financial Performance and Resilient Outlook Justify Buy Rating

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Sandoz Group...

12M ago

SDZNY FAQ

What was Sandoz Group Ltd Sponsored ADR’s price range in the past 12 months?

Sandoz Group Ltd Sponsored ADR lowest stock price was $36.26 and its highest was $86.79 in the past 12 months.

What is Sandoz Group Ltd Sponsored ADR’s market cap?

Sandoz Group Ltd Sponsored ADR’s market cap is $37.81B.

When is Sandoz Group Ltd Sponsored ADR’s upcoming earnings report date?

Sandoz Group Ltd Sponsored ADR’s upcoming earnings report date is Feb 25, 2026 which is in 4 days.

How were Sandoz Group Ltd Sponsored ADR’s earnings last quarter?

Sandoz Group Ltd Sponsored ADR released its earnings results on Aug 07, 2025. The company reported $0.882 earnings per share for the quarter, beating the consensus estimate of N/A by $0.882.

Is Sandoz Group Ltd Sponsored ADR overvalued?

According to Wall Street analysts Sandoz Group Ltd Sponsored ADR’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sandoz Group Ltd Sponsored ADR pay dividends?

Sandoz Group Ltd Sponsored ADR pays a Annually dividend of $0.727 which represents an annual dividend yield of 0.98%. See more information on Sandoz Group Ltd Sponsored ADR dividends here

What is Sandoz Group Ltd Sponsored ADR’s EPS estimate?

Sandoz Group Ltd Sponsored ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sandoz Group Ltd Sponsored ADR have?

Sandoz Group Ltd Sponsored ADR has 440,000,000 shares outstanding.

What happened to Sandoz Group Ltd Sponsored ADR’s price movement after its last earnings report?

Sandoz Group Ltd Sponsored ADR reported an EPS of $0.882 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 11.603%.

Which hedge fund is a major shareholder of Sandoz Group Ltd Sponsored ADR?

Currently, no hedge funds are holding shares in SDZNY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sandoz Group Ltd Sponsored ADR Stock Smart Score

Outperform

Fundamentals

Return on Equity

2.68%

Trailing 12-Months

Asset Growth

11.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sandoz Group Ltd Sponsored ADR

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.